Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133037949> ?p ?o ?g. }
- W2133037949 endingPage "1012" @default.
- W2133037949 startingPage "1000" @default.
- W2133037949 abstract "Abstract High-grade gliomas account for the majority of intra-axial brain tumors. Despite abundant therapeutic efforts, clinical outcome is still poor. Thus, new therapeutic approaches are intensely being investigated. Overexpression of the epidermal growth factor receptor (HER1/EGFR) is found in various epithelial tumors and represents one of the most common molecular abnormalities seen in high-grade gliomas. Dysregulated HER1/EGFR is found in 40% to 50% of glioblastoma, the most malignant subtype of glioma. Several agents such as tyrosine kinase (TK) inhibitors, antibodies, radio-immuno conjugates, ligand-toxin conjugates, or RNA-based agents have been developed to target HER1/EGFR or its mutant form, EGFRvIII. To date, most agents are in various stages of clinical development. Clinical data are sparse but most advanced for TK inhibitors. Although data from experimental studies seem promising, proof of a significant clinical benefit is still missing. Among the problems that have to be further addressed is the prediction of the individual patient's response to HER1/EGFR-targeted therapeutics based on molecular determinants. It is quite possible that blocking HER1/EGFR alone will not sufficiently translate into a clinical benefit. Therefore, a multiple target approach concomitantly aimed at different molecular sites might be a favorable concept. This review focuses on current HER1/EGFR-targeted therapeutics and their development for high-grade gliomas. (Mol Cancer Res 2009;7(7):1000–12)" @default.
- W2133037949 created "2016-06-24" @default.
- W2133037949 creator A5014073957 @default.
- W2133037949 creator A5015076723 @default.
- W2133037949 creator A5016488328 @default.
- W2133037949 creator A5087856756 @default.
- W2133037949 date "2009-07-01" @default.
- W2133037949 modified "2023-10-01" @default.
- W2133037949 title "Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?" @default.
- W2133037949 cites W131042380 @default.
- W2133037949 cites W1483388049 @default.
- W2133037949 cites W1521872585 @default.
- W2133037949 cites W1858161324 @default.
- W2133037949 cites W1910586263 @default.
- W2133037949 cites W1940514332 @default.
- W2133037949 cites W1966803171 @default.
- W2133037949 cites W1970083891 @default.
- W2133037949 cites W197014098 @default.
- W2133037949 cites W1970380373 @default.
- W2133037949 cites W1970510435 @default.
- W2133037949 cites W1987797739 @default.
- W2133037949 cites W1990995664 @default.
- W2133037949 cites W1995502732 @default.
- W2133037949 cites W1997226015 @default.
- W2133037949 cites W2001598945 @default.
- W2133037949 cites W2004957943 @default.
- W2133037949 cites W2011192975 @default.
- W2133037949 cites W2013245082 @default.
- W2133037949 cites W2013878898 @default.
- W2133037949 cites W2015848531 @default.
- W2133037949 cites W2016710415 @default.
- W2133037949 cites W2019995422 @default.
- W2133037949 cites W2020224707 @default.
- W2133037949 cites W2022132178 @default.
- W2133037949 cites W2030643073 @default.
- W2133037949 cites W2032090704 @default.
- W2133037949 cites W2036560693 @default.
- W2133037949 cites W2037077846 @default.
- W2133037949 cites W2038835567 @default.
- W2133037949 cites W2039856809 @default.
- W2133037949 cites W2042975893 @default.
- W2133037949 cites W2043696829 @default.
- W2133037949 cites W2048260140 @default.
- W2133037949 cites W2049292021 @default.
- W2133037949 cites W2050858145 @default.
- W2133037949 cites W2053535808 @default.
- W2133037949 cites W2061005093 @default.
- W2133037949 cites W2064047613 @default.
- W2133037949 cites W2064548992 @default.
- W2133037949 cites W2065285374 @default.
- W2133037949 cites W2065634769 @default.
- W2133037949 cites W2069336962 @default.
- W2133037949 cites W2070705072 @default.
- W2133037949 cites W2077648006 @default.
- W2133037949 cites W2083831897 @default.
- W2133037949 cites W2086554622 @default.
- W2133037949 cites W2088781966 @default.
- W2133037949 cites W2091102284 @default.
- W2133037949 cites W2091448236 @default.
- W2133037949 cites W2091707974 @default.
- W2133037949 cites W2095541301 @default.
- W2133037949 cites W2096287682 @default.
- W2133037949 cites W2100567246 @default.
- W2133037949 cites W2101099825 @default.
- W2133037949 cites W2101295929 @default.
- W2133037949 cites W2103894337 @default.
- W2133037949 cites W2104683360 @default.
- W2133037949 cites W2104743043 @default.
- W2133037949 cites W2105431194 @default.
- W2133037949 cites W2105505534 @default.
- W2133037949 cites W2106823541 @default.
- W2133037949 cites W2107232024 @default.
- W2133037949 cites W2108293816 @default.
- W2133037949 cites W2110719738 @default.
- W2133037949 cites W2113012900 @default.
- W2133037949 cites W2114292508 @default.
- W2133037949 cites W2115078677 @default.
- W2133037949 cites W2117941094 @default.
- W2133037949 cites W2118113452 @default.
- W2133037949 cites W2121057526 @default.
- W2133037949 cites W2125887187 @default.
- W2133037949 cites W2126148854 @default.
- W2133037949 cites W2127745545 @default.
- W2133037949 cites W2133282712 @default.
- W2133037949 cites W2137551916 @default.
- W2133037949 cites W2138297714 @default.
- W2133037949 cites W2139008103 @default.
- W2133037949 cites W2145683343 @default.
- W2133037949 cites W2150037470 @default.
- W2133037949 cites W2153477391 @default.
- W2133037949 cites W2154492869 @default.
- W2133037949 cites W2154670277 @default.
- W2133037949 cites W2154885678 @default.
- W2133037949 cites W2155152706 @default.
- W2133037949 cites W2157270051 @default.
- W2133037949 cites W2159566901 @default.
- W2133037949 cites W2161821474 @default.
- W2133037949 cites W2165254737 @default.